Literature DB >> 27033049

Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study.

Carrie Richardson1, Rishi Agrawal2, Jungwha Lee3, Orit Almagor4, Ryan Nelson5, John Varga4, Michael J Cuttica6, Jane D Amico Dematte6, Rowland W Chang7, Monique E Hinchcliff8.   

Abstract

OBJECTIVE: A patulous esophagus on high-resolution computed tomography (HRCT) of the thorax is frequently observed in patients with systemic sclerosis (SSc). Microaspiration has been purported to play a role in the development and progression of SSc interstitial lung disease (ILD), but studies examining the role of microaspiration in SSc ILD have yielded conflicting results. This study was conducted to determine the association between esophageal diameter and SSc ILD.
METHODS: A cross-sectional study of Northwestern Scleroderma Registry patients with available HRCT exams was conducted. The predictor variable was the widest esophageal diameter (WED) on HRCT, and the primary and secondary outcome variables were radiographic ILD and pulmonary function tests respectively. The degree of radiographic ILD was assessed using a semi-quantitative score adapted from published methods. Estimated regression coefficients adjusted for age, sex, race, body mass index, smoking; SSc disease subtype, serum autoantibodies, and disease duration; modified Rodnan skin score, proton pump inhibitor, and immune suppressant medication use and erythrocyte sedimentation rate were calculated.
RESULTS: A total of 270 subjects were studied. In the adjusted analyses, there were positive associations between WED and total ILD score (β = 0.27; 95% CI: 0.09-0.41), fibrosis (β = 0.15; 95% CI: 0.07-0.23), and ground glass opacities (β = 0.12; 95% CI: 0.04-0.20); there were negative associations between WED and FVC % predicted (β = -0.42; 95% CI: -0.69 to -0.13), and adjusted DLCO % predicted (β = -0.45; 95% CI: -0.80 to -0.09) after adjusting for potential confounders.
CONCLUSIONS: Increasing esophageal diameter on HRCT in patients with SSc is associated with more severe radiographic ILD, lower lung volumes, and lower DLCO % predicted. Longitudinal studies are needed to determine if esophageal dilatation is associated with the incidence and/or progression of ILD in patients with SSc.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dilation; Esophagus; Interstitial lung disease; Pulmonary fibrosis; Systemic sclerosis

Mesh:

Year:  2016        PMID: 27033049      PMCID: PMC5500283          DOI: 10.1016/j.semarthrit.2016.02.004

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  22 in total

1.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

2.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

3.  Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.

Authors:  Joyce S Lee; Jay H Ryu; Brett M Elicker; Carmen P Lydell; Kirk D Jones; Paul J Wolters; Talmadge E King; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2011-06-23       Impact factor: 21.405

4.  Oesophageal dysmotility in systemic sclerosis: comparison of HRCT and scintigraphy.

Authors:  E H Pitrez; M Bredemeier; R M Xavier; K G Capobianco; V G Restelli; M V Vieira; D H C Ludwig; J C T Brenol; A P A Furtado; L M B Fonseca; B Gutfilen
Journal:  Br J Radiol       Date:  2006-08-02       Impact factor: 3.039

5.  Chest CT in patients with scleroderma: prevalence of asymptomatic esophageal dilatation and mediastinal lymphadenopathy.

Authors:  M Bhalla; R M Silver; J A Shepard; T C McLoud
Journal:  AJR Am J Roentgenol       Date:  1993-08       Impact factor: 3.959

6.  Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis.

Authors:  Xuli Jerry Zhang; Ashley Bonner; Marie Hudson; Murray Baron; Janet Pope
Journal:  J Rheumatol       Date:  2013-04-01       Impact factor: 4.666

7.  Esophageal involvement and pulmonary manifestations in systemic sclerosis.

Authors:  I Marie; S Dominique; H Levesque; P Ducrotté; P Denis; M F Hellot; H Courtois
Journal:  Arthritis Rheum       Date:  2001-08

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

Review 9.  Pulmonary function tests.

Authors:  J Behr; D E Furst
Journal:  Rheumatology (Oxford)       Date:  2008-10       Impact factor: 7.580

10.  Oesophageal dilatation on high-resolution computed tomography scan of the lungs as a sign of scleroderma.

Authors:  M C Vonk; C E van Die; M M Snoeren; K J Bhansing; P L C M van Riel; J Fransen; F H J van den Hoogen
Journal:  Ann Rheum Dis       Date:  2007-12-28       Impact factor: 19.103

View more
  20 in total

Review 1.  Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.

Authors:  S Kumar; J Singh; S Rattan; A J DiMarino; S Cohen; S A Jimenez
Journal:  Aliment Pharmacol Ther       Date:  2017-02-09       Impact factor: 8.171

Review 2.  Gastrointestinal and Hepatic Disease in Systemic Sclerosis.

Authors:  Tracy M Frech; Diane Mar
Journal:  Rheum Dis Clin North Am       Date:  2018-02       Impact factor: 2.670

3.  Relationship between interstitial lung disease and oesophageal dilatation on chest high-resolution computed tomography in patients with systemic sclerosis: a cross-sectional study.

Authors:  Fausto Salaffi; Marco Di Carlo; Marina Carotti; Paolo Fraticelli; Armando Gabrielli; Andrea Giovagnoni
Journal:  Radiol Med       Date:  2018-04-23       Impact factor: 3.469

Review 4.  Lung Manifestations in the Rheumatic Diseases.

Authors:  Tracy J Doyle; Paul F Dellaripa
Journal:  Chest       Date:  2017-05-25       Impact factor: 9.410

5.  Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients.

Authors:  E K Stern; D A Carlson; S Falmagne; A D Hoffmann; M Carns; J E Pandolfino; M Hinchcliff; D M Brenner
Journal:  Neurogastroenterol Motil       Date:  2017-11-06       Impact factor: 3.598

6.  Comment on "Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study".

Authors:  Aileen Hoffmann; Jungwha Lee; Madeleine Ma; Rishi Agrawal; Rowland W Chang; Carrie Richardson; Monique Hinchcliff; Kimberly Showalter
Journal:  Semin Arthritis Rheum       Date:  2016-05-06       Impact factor: 5.532

Review 7.  GI Manifestations With a Focus on the Esophagus: Recent Progress in Understanding Pathogenesis.

Authors:  Marie-Pier Tétreault; Peter Kahrilas
Journal:  Curr Rheumatol Rep       Date:  2019-07-03       Impact factor: 4.592

8.  Esophageal Dilatation as a Predictor of Systemic Sclerosis in Patients with Interstitial Lung Disease.

Authors:  Ana Filipa Santos Duarte de Figueiredo; João Felício Costa; António P Matos; Miguel Ramalho
Journal:  Turk Thorac J       Date:  2021-05

9.  Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis.

Authors:  Kimberly Showalter; Aileen Hoffmann; Carrie Richardson; David Aaby; Jungwha Lee; Jane Dematte; Rishi Agrawal; Hatice Savas; Xiaoping Wu; Rowland W Chang; Monique Hinchcliff
Journal:  J Rheumatol       Date:  2021-07-15       Impact factor: 4.666

Review 10.  Esophageal manifestation in patients with scleroderma.

Authors:  Theodoros A Voulgaris; Georgios P Karamanolis
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.